SmPC - Lopinavir/Ritonavir Accord 200 mg/50 mg Film-coated Tablets: Change history
View Summary of Product Characteristics (SmPC - Lopinavir/Ritonavir Accord 200 mg/50 mg Film-coated Tablets)
Last updated on this site: 11 Apr 2023
Description of update: To update SmPC and PIL in-line with the product information of reference product (Kaletra 200 mg/50 mg film-coated tablets, EU procedure number: EU/1/01/172/001-006; MAH: AbbVie Deutschland GmbH & Co. KG, Germany) for Lopinavir/Ritonavir 200mg/50mg film-coated tablets.
SmPC sections updated: 4.3, 4.4, 4.5, 4.6, 4.8, 5.2, 10
View Summary of Product Characteristics (SmPC - Lopinavir/Ritonavir Accord 200 mg/50 mg Film-coated Tablets)
Last updated on this site: 11 Apr 2023
Description of update: To update SmPC and PIL in-line with the product information of reference product (Kaletra 200 mg/50 mg film-coated tablets, EU procedure number: EU/1/01/172/001-006; MAH: AbbVie Deutschland GmbH & Co. KG, Germany) for Lopinavir/Ritonavir 200mg/50mg film-coated tablets.
SmPC sections updated: 4.3, 4.4, 4.5, 4.6, 4.8, 5.2, 10
-
Changes: (Updated: 11 Apr 2023)
Description of update: To update SmPC and PIL in-line with the product information of reference product (Kaletra 200 mg/50 mg film-coated tablets, EU procedure number: EU/1/01/172/001-006; MAH: AbbVie Deutschland GmbH & Co. KG, Germany) for Lopinavir/Ritonavir 200mg/50mg film-coated tablets.
SmPC sections updated: 4.3, 4.4, 4.5, 4.6, 4.8, 5.2, 10
-
Changes: (Updated: 21 Sep 2022)
Initial upload